MX2018015567A - Combinacion que comprende antagonista del receptor 4 de prostaglandina e2 (ep4) e inhibidor de punto de control inmunitario. - Google Patents
Combinacion que comprende antagonista del receptor 4 de prostaglandina e2 (ep4) e inhibidor de punto de control inmunitario.Info
- Publication number
- MX2018015567A MX2018015567A MX2018015567A MX2018015567A MX2018015567A MX 2018015567 A MX2018015567 A MX 2018015567A MX 2018015567 A MX2018015567 A MX 2018015567A MX 2018015567 A MX2018015567 A MX 2018015567A MX 2018015567 A MX2018015567 A MX 2018015567A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- immune checkpoint
- checkpoint inhibitor
- antagonist
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención aborda el problema de descubrir un método eficaz de terapia contra el cáncer y proporcionar un medicamento. Se proporciona un medicamento que comprende una combinación de un compuesto representado por la fórmula general (I), una sal, solvato o N-óxido del compuesto o un profármaco del compuesto o la sal, solvato o N-óxido y un inhibidor del punto de control inmunitario (por ejemplo, un anticuerpo anti-PD-1). La combinación de acuerdo con la presente invención exhibe un alto efecto antitumoral y, por lo tanto, es útil para el tratamiento del cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359504P | 2016-07-07 | 2016-07-07 | |
| PCT/JP2017/024753 WO2018008711A1 (ja) | 2016-07-07 | 2017-07-06 | Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018015567A true MX2018015567A (es) | 2019-06-06 |
| MX385428B MX385428B (es) | 2025-03-04 |
Family
ID=60912958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015567A MX385428B (es) | 2016-07-07 | 2017-07-06 | Combinación que comprende antagonista del receptor 4 de prostaglandina e2 (ep4) e inhibidor de punto de control inmunitario. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11065226B2 (es) |
| EP (1) | EP3482760B1 (es) |
| JP (2) | JP6323629B1 (es) |
| KR (1) | KR102473601B1 (es) |
| CN (1) | CN109475520B (es) |
| AU (1) | AU2017292522B2 (es) |
| CA (1) | CA3029611A1 (es) |
| DK (1) | DK3482760T3 (es) |
| ES (1) | ES2900306T3 (es) |
| HU (1) | HUE057799T2 (es) |
| IL (1) | IL264063B (es) |
| MX (1) | MX385428B (es) |
| MY (1) | MY197673A (es) |
| PH (1) | PH12019500002B1 (es) |
| PL (1) | PL3482760T3 (es) |
| PT (1) | PT3482760T (es) |
| RU (1) | RU2748731C2 (es) |
| SG (1) | SG11201811591UA (es) |
| TW (2) | TWI795362B (es) |
| WO (1) | WO2018008711A1 (es) |
| ZA (1) | ZA201900060B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3255624B2 (ja) | 1998-07-03 | 2002-02-12 | 日本電信電話株式会社 | コネクタプラグおよび光コネクタ |
| CN107108480B (zh) * | 2015-01-09 | 2020-01-17 | 小野药品工业株式会社 | 三环螺环化合物 |
| IL270021B (en) | 2017-04-18 | 2022-08-01 | Tempest Therapeutics Inc | Bicyclic compounds and their use in the treatment of cancer |
| US10617667B2 (en) | 2017-11-01 | 2020-04-14 | Ono Pharmaceutical Co., Ltd. | Method for treating brain tumors |
| WO2019149286A1 (en) * | 2018-02-05 | 2019-08-08 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases |
| CN110156674A (zh) * | 2018-02-13 | 2019-08-23 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
| AU2019255196A1 (en) * | 2018-04-16 | 2020-11-12 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| DK3781550T3 (da) | 2018-04-17 | 2025-01-27 | Tempest Therapeutics Inc | Bicykliske carboxamider og fremgangsmåder til anvendelse deraf |
| US20210315909A1 (en) | 2018-07-11 | 2021-10-14 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP3722319A1 (en) * | 2019-04-09 | 2020-10-14 | Rottapharm Biotech S.r.l. | Pharmaceutical combination of an ep4 antagonist and immune checkpoint inhibitors for the treatment of tumours |
| WO2020242773A1 (en) * | 2019-05-31 | 2020-12-03 | Clear Creek Bio, Inc. | Methods of promoting differentiation of myeloid-derived suppressor cells using inhibitors of dihydroorotate dehydrogenase |
| CN110386941A (zh) * | 2019-08-15 | 2019-10-29 | 上海邦耀生物科技有限公司 | Ep4受体拮抗剂和pd-1抑制剂联合用于癌症的治疗 |
| IL294196A (en) * | 2019-12-25 | 2022-08-01 | Nippon Shinyaku Co Ltd | Antitumor drug for use in combination with an immune checkpoint inhibitor |
| EP4117665A4 (en) * | 2020-03-10 | 2024-04-17 | Emory University | METHODS OF TREATING CANCER WITH CHECKPOINT INHIBITORS IN COMBINATION WITH PURINE-CLIPPING ENZYMES |
| US20230390303A1 (en) * | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| CN114790186A (zh) * | 2021-01-25 | 2022-07-26 | 武汉人福创新药物研发中心有限公司 | 作为ep4拮抗剂的稠环化合物及其制备方法和用途 |
| WO2022247862A1 (zh) * | 2021-05-28 | 2022-12-01 | 南京明德新药研发有限公司 | 苯并螺杂环衍生物及其应用 |
| US20250002448A1 (en) * | 2021-09-21 | 2025-01-02 | Merck Sharp & Dohme Llc | Allosteric modulators of nicotinic acetylcholine receptors |
| CN119031933B (zh) * | 2022-04-12 | 2025-08-26 | 正大天晴(广州)医药有限公司 | 蛋白酶体抑制剂与抗pd-1抗体的药物组合 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999047497A2 (en) | 1998-03-13 | 1999-09-23 | Merck Frosst Canada & Co. | Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| AU2001278771A1 (en) | 2000-08-22 | 2002-03-04 | Ono Pharmaceutical Co. Ltd. | Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient |
| KR20040022238A (ko) | 2001-08-09 | 2004-03-11 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제 |
| EP2114877B1 (en) | 2007-02-26 | 2012-12-26 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| KR102535283B1 (ko) * | 2014-05-23 | 2023-05-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 암의 치료를 위한 조합 요법 |
| CN107108480B (zh) | 2015-01-09 | 2020-01-17 | 小野药品工业株式会社 | 三环螺环化合物 |
-
2017
- 2017-07-06 HU HUE17824314A patent/HUE057799T2/hu unknown
- 2017-07-06 TW TW106122678A patent/TWI795362B/zh active
- 2017-07-06 EP EP17824314.3A patent/EP3482760B1/en active Active
- 2017-07-06 KR KR1020197000093A patent/KR102473601B1/ko active Active
- 2017-07-06 DK DK17824314.3T patent/DK3482760T3/da active
- 2017-07-06 US US16/315,063 patent/US11065226B2/en active Active
- 2017-07-06 MY MYPI2018002961A patent/MY197673A/en unknown
- 2017-07-06 PH PH1/2019/500002A patent/PH12019500002B1/en unknown
- 2017-07-06 ES ES17824314T patent/ES2900306T3/es active Active
- 2017-07-06 WO PCT/JP2017/024753 patent/WO2018008711A1/ja not_active Ceased
- 2017-07-06 PT PT178243143T patent/PT3482760T/pt unknown
- 2017-07-06 SG SG11201811591UA patent/SG11201811591UA/en unknown
- 2017-07-06 CN CN201780042306.5A patent/CN109475520B/zh active Active
- 2017-07-06 PL PL17824314T patent/PL3482760T3/pl unknown
- 2017-07-06 RU RU2018146479A patent/RU2748731C2/ru active
- 2017-07-06 TW TW111107751A patent/TWI805255B/zh active
- 2017-07-06 AU AU2017292522A patent/AU2017292522B2/en active Active
- 2017-07-06 MX MX2018015567A patent/MX385428B/es unknown
- 2017-07-06 CA CA3029611A patent/CA3029611A1/en active Pending
- 2017-07-06 JP JP2017559144A patent/JP6323629B1/ja active Active
-
2018
- 2018-03-20 JP JP2018053140A patent/JP7020218B2/ja active Active
-
2019
- 2019-01-02 IL IL264063A patent/IL264063B/en unknown
- 2019-01-04 ZA ZA2019/00060A patent/ZA201900060B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500002A1 (en) | Combination comprising ep4 antagonist and immune checkpoint inhibitor | |
| MX2018004643A (es) | Compuestos de benzolactama como inhibidores de la proteina cinasa. | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| EP4302835A3 (en) | Methods of treating ovarian cancer | |
| PH12017502363A1 (en) | Brk inhibitory compound | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| MX383880B (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| UA117976C2 (uk) | Сполуки амінопіримідинілу як інгібітори jak | |
| MX377560B (es) | Inhibidor de cinasa aurora a. | |
| MY189557A (en) | Pyridone compound as c-met inhibitor | |
| JO3722B1 (ar) | مثبطات 6-(5- هيدروكسي-1h- بيرازول-1- يل) و مشتقات نيكوتيناميد واستخدامها كمثبطات | |
| EA201992320A1 (ru) | Пиперидины в качестве ковалентных ингибиторов менина | |
| EA201790327A1 (ru) | Соединения замещенного пиперидина | |
| EA201790779A1 (ru) | Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений | |
| MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| EA201792320A1 (ru) | Способ лечения рака ингибитором пути stat3 и ингибитором киназы | |
| EA201792288A1 (ru) | Способы лечения рака | |
| MX2020012292A (es) | Compuestos para el tratamiento de cáncer de pancreas. | |
| CY1119540T1 (el) | Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt | |
| EA201892698A1 (ru) | Производные пиразолиламинобензимидазола в качестве ингибиторов jak | |
| HK1243407A1 (zh) | Ripk2抑制剂及用其治疗癌症的方法 |